{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:46:15Z","timestamp":1784547975817,"version":"3.55.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2021.711080","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:43:09Z","timestamp":1624524189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Editorial: Immunology of Vitiligo"],"prefix":"10.3389","volume":"12","author":[{"given":"Julien","family":"Seneschal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Caroline","family":"Le Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhart","family":"Speeckaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: Mechanisms of Pathogenesis and Treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","article-title":"Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy","volume":"54","author":"Boniface","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10650.x","article-title":"New Insights in Segmental Vitiligo: Case Report and Review of Theories","volume":"166","author":"van Geel","year":"2012","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13879","article-title":"Vitiligo as a Skin Memory Disease: The Need for Early Intervention With Immunomodulating Agents and a Maintenance Therapy to Target Resident Memory T Cells","volume":"28","author":"Boniface","year":"2019","journal-title":"Exp Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900027","article-title":"The Role of Memory Cd8+ T Cells in Vitiligo","volume":"203","author":"Riding","year":"2019","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12949","article-title":"An Update on Vitiligo Pathogenesis","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.autrev.2014.10.002","article-title":"Regulatory T Cells in Vitiligo: Implications for Pathogenesis and Therapeutics","volume":"14","author":"Dwivedi","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102761","article-title":"Engineered Antigen-Specific Regulatory T Cells for Autoimmune Skin Conditions","volume":"20","author":"Mukhatayev","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib Cream for Treatment of Vitiligo: A Randomised, Controlled, Phase 2 Trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30747-9","article-title":"First Step in a New Era for Treatment of Patients With Vitiligo","volume":"396","author":"Passeron","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.711080\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:43:11Z","timestamp":1624524191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.711080\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2021.711080"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.711080","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"article-number":"711080"}}